EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients

Riikka Gunnar iD, Annika Mutanen, Mikko P Pakarinen, Laura Merras-Salmio

Journal of Pediatric Gastroenterology and Nutrition · 2026-07 · 83 (1) · 37-45

DOI: 10.1002/jpn3.70437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 09.04.2026. Verfasst von Riikka Gunnar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology Unit, Helsinki University Children's Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Peptides, Gastrointestinal Agents, Intestinal Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sigrid Juséliuksen Säätiö, Mary och Georg C. Ehrnrooths Stiftelse, Helsingin Yliopisto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We evaluated the efficacy and safety of teduglutide in a real‐world cohort in which national reimbursement policies required treatment interruptions. The primary outcomes were reduction in parenteral support (PS) and treatment‐related adverse effects, and the secondary outcome was the impact of the mandated withdrawal periods.

Methods

In this retrospective registry‐based nationwide study, we identified all pediatric short bowel–associated intestinal failure (IF) patients treated with teduglutide and reviewed clinical records to evaluate PS reduction and adverse effects during treatment and withdrawal.

Results

Twenty pediatric IF patients had teduglutide initiated (age range: 1.4–17 years) between 2016 and 2022. Patients had a median 16% small bowel remaining, and 16 (79%) had the ileocecal valve removed. Children who continued teduglutide over 6 months ( n = 19) had a median of 31 (range: 13–56) months of follow‐up on medication. Their median reductions in daily PS energy and fluid volume requirement were 42% and 28 mL/kg/day, respectively. Weekly infusion‐free nights increased from 0.5 to 4. Seventeen (89%) patients reached >20% energy reduction. Six patients (32%) successfully weaned off PS. Four patients (20%) experienced intestinal bleeding while on teduglutide. Stomal prolapses occurred in all patients with end‐jejunostomies. Periodic withdrawal ( n = 37) led to adverse effects on 84% of occasions ( n = 32), including two unplanned hospitalizations and 14 (38%) outpatient visits, dehydration in 19 (51%), and diarrhea in 28 (76%) occasions.

Conclusions

Teduglutide resulted in clinically significant PS reduction and increased infusion‐free nights. The periodic withdrawal of teduglutide was harmful and should not be routinely employed. Trial Registration ClinicalTrials.gov identifier: HUS/265/2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Short Bowel SyndromePeptidesGastrointestinal AgentsIntestinal FailureHumansRetrospective StudiesFemaleChild, PreschoolInfantMaleAdolescentChildTreatment OutcomeParenteral NutritionRegistriesTreatment Interruption

Stichwörter der Autor:innen

anastomotic ulcerintestinal failureparenteral nutrition

Substanzen

teduglutidePeptidesGastrointestinal Agents

Autor:innen und Institutionen

  • Pediatric Gastroenterology Unit, Helsinki University Children's Hospital, Helsinki, Finland.
  • The Pediatric Research Center, University of Helsinki, Helsinki, Finland.
  • Pediatric Surgery Department, Helsinki University Children's Hospital, Helsinki, Finland.

ORCID-Profile: Riikka Gunnar

Förderung

  • Sigrid Juséliuksen Säätiö
  • Mary och Georg C. Ehrnrooths Stiftelse
  • Helsingin Yliopisto
  • Helsingin ja Uudenmaan Sairaanhoitopiiri
  • Lastentautien Tutkimussäätiö
  • Mary and Georg C. Ehnrooth Foundation
  • Helsinki University Hospital Research Fund
  • Sigrid Jusélius Foundation

Zitieren

APA

Gunnar, R., Mutanen, A., Pakarinen, M. P., & Merras-Salmio, L. (2026). Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients. Journal of Pediatric Gastroenterology and Nutrition, 83(1), 37-45. https://doi.org/10.1002/jpn3.70437

Vancouver

Gunnar R, Mutanen A, Pakarinen MP, Merras-Salmio L. Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients. Journal of Pediatric Gastroenterology and Nutrition. 2026;83(1):37-45. doi:10.1002/jpn3.70437

BibTeX
@article{Gunnar2026,
  author = {Gunnar, Riikka and Mutanen, Annika and Pakarinen, Mikko P and Merras-Salmio, Laura},
  title = {Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  volume = {83},
  number = {1},
  pages = {37--45},
  doi = {10.1002/jpn3.70437}
}
Kostenlos starten →